Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity.

Cervenak J, Kurrle R, Kacskovics I.

Immunol Rev. 2015 Nov;268(1):269-87. doi: 10.1111/imr.12364. Review.

PMID:
26497527
2.

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.

Sommerfeld MR, Müller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N.

PLoS One. 2010 Mar 4;5(3):e9540. doi: 10.1371/journal.pone.0009540.

3.

ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs.

Randle JC, Harding MW, Ku G, Schönharting M, Kurrle R.

Expert Opin Investig Drugs. 2001 Jul;10(7):1207-9. Review.

PMID:
11772244
4.

The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine.

Czech J, Kurrle R, Schorlemmer HU.

Inflamm Res. 1999 Dec;48 Suppl 2:S128-9. No abstract available.

PMID:
10667848
5.

Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite.

Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR.

Inflamm Res. 1999 Dec;48 Suppl 2:S117-8. No abstract available.

PMID:
10667842
6.

Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis.

Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR.

Inflamm Res. 1999 Dec;48 Suppl 2:S113-4. No abstract available.

PMID:
10667840
7.

In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.

Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR.

Inflamm Res. 1999 Dec;48 Suppl 2:S111-2. No abstract available.

PMID:
10667839
8.

Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model.

Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R.

Transplant Proc. 1999 Feb-Mar;31(1-2):1184-8. No abstract available.

PMID:
10083529
9.

Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model.

Schorlemmer HU, Bartlett RR, Kurrle R.

Transplant Proc. 1999 Feb-Mar;31(1-2):851-3. No abstract available.

PMID:
10083371
10.

Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival.

Schorlemmer HU, Kurrle R.

Transplant Proc. 1998 Dec;30(8):4170-3. No abstract available.

PMID:
9865337
11.

Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus.

Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R.

Transplant Proc. 1998 Dec;30(8):4099-103. No abstract available.

PMID:
9865312
12.

The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness.

Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU.

J Immunol. 1998 Dec 15;161(12):6871-7.

13.

HIV/gp120 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas-L upregulation.

Accornero P, Radrizzani M, Carè A, Mattia G, Chiodoni C, Kurrle R, Colombo MP.

FEBS Lett. 1998 Oct 9;436(3):461-5.

14.

A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement.

Siefken R, Klein-Hessling S, Serfling E, Kurrle R, Schwinzer R.

J Immunol. 1998 Aug 15;161(4):1645-51.

15.

Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides.

Schorlemmer HU, Ruuth E, Kurrle R.

Transpl Int. 1998;11 Suppl 1:S448-51.

PMID:
9665036
16.

Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine.

Schorlemmer HU, Ruuth E, Kurrle R.

Transpl Int. 1998;11 Suppl 1:S340-4.

PMID:
9665012
17.

Malononitrilamides reduce IgM and IgG xenoantibodies and prolong skin xenograft survival in a mouse-to rat model.

Schorlemmer HU, Kurrle R.

Transplant Proc. 1998 Jun;30(4):976-9. No abstract available.

PMID:
9636394
18.

Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides.

Schorlemmer HU, Bartlett RR, Kurrle R.

Transplant Proc. 1998 Jun;30(4):968-70. No abstract available.

PMID:
9636391
19.

Hyperacute skin allograft rejection in presensitized rats is abrogated by malononitrilamides.

Schorlemmer HU, Kurrle R.

Transplant Proc. 1998 Jun;30(4):963-7. No abstract available.

PMID:
9636390
20.

Malononitrilamides: a new strategy of immunosuppression for allo- and xenotransplantation.

Schorlemmer H, Bartlett R, Kurrle R.

Transplant Proc. 1998 May;30(3):884-90. Review. No abstract available.

PMID:
9595136
21.

Costimulation via TCR and IL-1 receptor reveals a novel IL-1alpha-mediated autocrine pathway of Th2 cell proliferation.

Huber M, Beuscher HU, Rohwer P, Kurrle R, Röllinghoff M, Lohoff M.

J Immunol. 1998 May 1;160(9):4242-7.

22.

Long-term xenograft survival by combination therapy of malononitrilamide MNA 715 with cyclosporine.

Schorlemmer HU, Kurrle R.

Transplant Proc. 1997 Dec;29(8):3501-4. No abstract available.

PMID:
9414811
23.

The new immunosuppressive malononitrilamide MNA 279 prolongs skin xenograft survival in a mouse-to-rat model.

Schorlemmer HU, Kurrle R.

Transplant Proc. 1997 Dec;29(8):3497-500. No abstract available.

PMID:
9414810
24.

Apoptosis of CD4+ and CD8+ T cells isolated immediately ex vivo correlates with disease severity in human immunodeficiency virus type 1 infection.

Cotton MF, Ikle DN, Rapaport EL, Marschner S, Tseng PO, Kurrle R, Finkel TH.

Pediatr Res. 1997 Nov;42(5):656-64.

PMID:
9357940
25.

Molecular characterization and functional analysis of murine interleukin 4 receptor allotypes.

Schulte T, Kurrle R, Röllinghoff M, Gessner A.

J Exp Med. 1997 Nov 3;186(9):1419-29.

26.

Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs).

Schorlemmer HU, Kurrle R, Bartlett RR.

Inflamm Res. 1997 Aug;46 Suppl 2:S165-6. No abstract available.

PMID:
9297563
27.

Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering.

Radrizzani M, Accornero P, Delia D, Kurrle R, Colombo MP.

FEBS Lett. 1997 Jul 7;411(1):87-92.

28.

CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex.

Siefken R, Kurrle R, Schwinzer R.

Cell Immunol. 1997 Feb 25;176(1):59-65.

PMID:
9070318
29.

Malononitrilamides inhibit T- and B-cell responsiveness in different species.

Kurrle R, Ruuth E, Bartlett R, Lauffer L, Schorlemmer HU.

Transplant Proc. 1997 Feb-Mar;29(1-2):1302-3. No abstract available.

PMID:
9123316
30.

Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease.

Schorlemmer HU, Bartlett RR, Kurrle R.

Transplant Proc. 1997 Feb-Mar;29(1-2):1298-301. No abstract available.

PMID:
9123315
31.

Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions.

Accornero P, Radrizzani M, Delia D, Gerosa F, Kurrle R, Colombo MP.

Blood. 1997 Jan 15;89(2):558-69.

PMID:
9002959
32.
33.

The alloreactivity in the popliteal lymph node (PLN) assay is regulated by malononitrilamides (MNAs).

Schorlemmer HU, Ruuth E, Kurrle R.

Int J Tissue React. 1997;19(3-4):157-61.

PMID:
9506317
34.

Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection.

Schorlemmer HU, Kurrle R.

Int J Tissue React. 1997;19(3-4):149-56.

PMID:
9506316
35.

Malononitrilamides inhibit T- and B-cell responsiveness.

Kurrle R, Bartlett R, Ruuth E, Lauffer L, Schorlemmer HU.

Transplant Proc. 1996 Dec;28(6):3053-6. No abstract available.

PMID:
8962184
36.

Acute skin graft rejection can be prevented and treated in rat models by malononitrilamides.

Schorlemmer HU, Schwab W, Ruuth E, Kurrle R.

Transplant Proc. 1996 Dec;28(6):3048-50. No abstract available.

PMID:
8962182
37.

Malononitrilamides inhibit the development of various murine graft-vs-host diseases.

Schorlemmer HU, Kurrle R, Bartlett RR.

Transplant Proc. 1996 Dec;28(6):3043-7. No abstract available.

PMID:
8962181
38.

Control of mouse-to-rat skin xenograft rejection by malononitrilamides.

Schorlemmer HU, Kurrle R.

Transplant Proc. 1996 Dec;28(6):3037-9. No abstract available.

PMID:
8962179
39.

alpha/beta-T cell receptor-directed therapy in rat allograft recipients. Long-term survival of cardiac allografts after pretreatment with R73 mAb is associated with upregulation of Th2-type cytokines.

Heidecke CD, Hancock WW, Westerholt S, Sewczik T, Jakobs F, Zantl N, Varzaru A, Siegling A, Kurrle R, Deusch K, Volk HD, Kupiec-Weglinski JW.

Transplantation. 1996 Mar 27;61(6):948-56.

PMID:
8623165
40.

Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis.

Tam FW, Karkar AM, Smith J, Yoshimura T, Steinkasserer A, Kurrle R, Langner K, Rees AJ.

Kidney Int. 1996 Mar;49(3):715-21.

41.

Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor.

Karkar AM, Tam FW, Steinkasserer A, Kurrle R, Langner K, Scallon BJ, Meager A, Rees AJ.

Kidney Int. 1995 Dec;48(6):1738-46.

42.

Soluble interleukin-4 receptor in atopic children.

Schauer U, Schmitt M, Müller S, Enssle K, Kurrle R, Sundermann U, Bender A, Wahn U, Rieger CH.

Int Arch Allergy Immunol. 1995 Oct;108(2):175-82.

PMID:
7549506
43.

Regulation of IL-1 activity by soluble IL-1 receptors.

Kurrle R, Lauffer L, Röder J, Kanzy EJ, Enssle KH, Seiler FR.

Behring Inst Mitt. 1995 Jun;(96):45-57. Review. No abstract available.

PMID:
7575352
44.

Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential.

Lauffer L, Kanzy EJ, Köhler R, Kurrle R, Enssle K, Seiler FR.

Behring Inst Mitt. 1995 Jun;(96):21-31.

PMID:
7575349
45.

Biology of natural and recombinant soluble interleukin-4 receptor.

Enssle K, Enders B, Kurrle R, Lauffer L, Schorlemmer HU, Dickneite G, Kanzy EJ, Seiler FR.

Behring Inst Mitt. 1995 Jun;(96):103-17. Review. No abstract available.

PMID:
7575346
46.
47.

IL-12 inhibits apoptosis induced in a human Th1 clone by gp120/CD4 cross-linking and CD3/TCR activation or by IL-2 deprivation.

Radrizzani M, Accornero P, Amidei A, Aiello A, Delia D, Kurrle R, Colombo MP.

Cell Immunol. 1995 Mar;161(1):14-21.

PMID:
7867080
48.

Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats.

Schorlemmer HU, Dickneite G, Kurrle R, Seiler FR.

Transplant Proc. 1995 Feb;27(1):414-6. No abstract available.

PMID:
7879044
49.

alpha/beta-T cell receptor-directed therapy in rat cardiac allograft recipients. Treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection.

Heidecke CD, Hancock WW, Jakobs F, Zantl N, Kurrle R, Westerholt S, Sewczik T, Deusch K, Kupiec-Weglinski J.

Transplantation. 1995 Jan 15;59(1):78-84.

PMID:
7839433
50.

Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor.

Renz H, Enssle K, Lauffer L, Kurrle R, Gelfand EW.

Int Arch Allergy Immunol. 1995 Jan;106(1):46-54.

PMID:
7812166

Supplemental Content

Loading ...
Support Center